Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

null 陳榮楷; null 吳秋文; null 林增熙; null 季匡華; null 趙毅; null 黃以信; null 吳銘芳; null 陳育民; null 劉敏; Jacqueline 彭汪嘉康; null 李壽東; null 雷永耀

doi:10.6316/TRO/199401(3)255

Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

貢獻的翻譯標題: Cisplatin，5-Fluorouracil，Leucovorin治療頑固性胃癌

陳榮楷, 吳秋文, 林增熙, 季匡華, 趙毅, 黃以信, 吳銘芳, 陳育民, 劉敏, 彭汪嘉康, 李壽東, 雷永耀

研究成果: 雜誌貢獻 › 文章 › 同行評審

摘要

罹患晚期胃癌且對第一線化學治療失敗後的預後非常差。然而，卻少見有效的化學治療可用來對抗這種晚期頑固性胃癌。基於PFL療法在胃癌、鼻咽癌等癌病有令人鼓舞的療效，我們導引此前期研究來評估PFL在晚期頑固性胃癌的療效。研究方法是選擇可測量之晚期頑固性胃癌病人，每三星期為一療程，給予每天每平方公尺體表面積混合之Cisplatin20毫克，5-FU 800毫克，Leucovorin 90毫克，經靜脈滴注96小時，並評估治療反應、存活期及毒性反應。結果，共有20位病人進入此研究，只有15位可評估治療反應，無一例完全緩解，有四位達部份緩解，緩解率達27%。全部的毒性之耐受度相當好，主要的毒性是口腔黏膜炎及白血球缺乏。無第四級毒性或治療相關之死亡。結論：用PFL治療頑固性胃癌是安全且可能有效的療法，但仍需進一步的評估。

貢獻的翻譯標題	Cisplatin，5-Fluorouracil，Leucovorin治療頑固性胃癌
原文	英語
頁（從 - 到）	255-262
頁數	8
期刊	放射治療與腫瘤學
卷	1
發行號	3
DOIs	https://doi.org/10.6316/TRO/199401(3)255
出版狀態	已發佈 - 1994
對外發佈	是

Keywords

Cisplatin
5-Fluorouracil
Leucovorin
Refractory Gastric Cancer
Fluorouracil

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.6316/TRO/199401(3)255

引用此

@article{bde3db3a0d6746a9ab3ea37a1dfbd659,

title = "Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients",

abstract = "Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.",

keywords = "Cisplatin, 5-Fluorouracil, 頑固性胃癌, leucovorin, Fluorouracil, Cisplatin, 5-Fluorouracil, Leucovorin, Refractory Gastric Cancer, Fluorouracil",

author = "陳榮楷 and 吳秋文 and 林增熙 and 季匡華 and 趙毅 and 黃以信 and 吳銘芳 and 陳育民 and 劉敏 and 彭汪嘉康 and 李壽東 and 雷永耀",

year = "1994",

doi = "10.6316/TRO/199401(3)255",

language = "English",

volume = "1",

pages = "255--262",

journal = "放射治療與腫瘤學",

issn = "1023-988x",

publisher = "台灣放射腫瘤學會",

number = "3",

}

TY - JOUR

T1 - Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

AU - 陳榮楷, null

AU - 吳秋文, null

AU - 林增熙, null

AU - 季匡華, null

AU - 趙毅, null

AU - 黃以信, null

AU - 吳銘芳, null

AU - 陳育民, null

AU - 劉敏, null

AU - 彭汪嘉康, null

AU - 李壽東, null

AU - 雷永耀, null

PY - 1994

Y1 - 1994

N2 - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.

AB - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.

KW - Cisplatin

KW - 5-Fluorouracil

KW - 頑固性胃癌

KW - leucovorin

KW - Fluorouracil

KW - Cisplatin

KW - 5-Fluorouracil

KW - Leucovorin

KW - Refractory Gastric Cancer

KW - Fluorouracil

U2 - 10.6316/TRO/199401(3)255

DO - 10.6316/TRO/199401(3)255

M3 - Article

VL - 1

SP - 255

EP - 262

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

SN - 1023-988x

IS - 3

ER -

Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

摘要

Keywords

UN SDG

存取文件

指紋

引用此